Sunday, May 20, 2007 9:03:23 PM
ANX - Adventrx Pharmaceuticals Inc.
ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical research and development company, focuses on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The company's lead product candidate, ANX-510, or CoFactor, is in Phase III and Phase IIb clinical trials for the treatment of metastatic colorectal cancer, as well as in a Phase II clinical trial for the treatment of advanced breast cancer. Its other product candidate, ANX-530, a new formulation of vinorelbine tartrate, is in a marketing-enabling clinical trial for the treatment of non-small cell lung cancer. In addition, ADVENTRX has other compounds in its oncology program development portfolio that the company is evaluating for future preclinical and clinical development, including ANX-570, a formulation of beta-elemene, a small molecule anticancer agent belonging to the triterpene family, and ANX-575, an emulsion formulation of alpha-tocopheryl succinate.
News .. Financial Highlights .. Analyst Estimates .. Option Chain .. IV ..Candlestick Analysis..Short Interest.
.
.
ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical research and development company, focuses on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The company's lead product candidate, ANX-510, or CoFactor, is in Phase III and Phase IIb clinical trials for the treatment of metastatic colorectal cancer, as well as in a Phase II clinical trial for the treatment of advanced breast cancer. Its other product candidate, ANX-530, a new formulation of vinorelbine tartrate, is in a marketing-enabling clinical trial for the treatment of non-small cell lung cancer. In addition, ADVENTRX has other compounds in its oncology program development portfolio that the company is evaluating for future preclinical and clinical development, including ANX-570, a formulation of beta-elemene, a small molecule anticancer agent belonging to the triterpene family, and ANX-575, an emulsion formulation of alpha-tocopheryl succinate.
News .. Financial Highlights .. Analyst Estimates .. Option Chain .. IV ..Candlestick Analysis..Short Interest.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
